Compare ASYS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASYS | IPHA |
|---|---|---|
| Founded | 1981 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 160.7M |
| IPO Year | 2006 | N/A |
| Metric | ASYS | IPHA |
|---|---|---|
| Price | $12.98 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 171.8K | 12.9K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $79,364,000.00 | N/A |
| Revenue This Year | $2.82 | $28.31 |
| Revenue Next Year | $18.75 | N/A |
| P/E Ratio | $1,278.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $1.40 |
| 52 Week High | $18.59 | $2.63 |
| Indicator | ASYS | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 31.04 |
| Support Level | $11.60 | N/A |
| Resistance Level | $13.26 | $1.88 |
| Average True Range (ATR) | 0.79 | 0.08 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 47.20 | 2.53 |
Amtech Systems Inc provides equipment, consumables and services for semiconductor device packaging, wafer production and device fabrication. Its products are used to fabricate and package GPUs for AI applications, SiC and Si power devices, and other optical, analog and digital devices, and are sold to semiconductor packaging, electronic assembly and device fabrication companies. It operates through two segments: Thermal Processing Solutions, which includes conveyorized reflow equipment, high-temperature conveyorized furnaces and diffusion furnaces with maximum revenue; and Semiconductor Fabrication Solutions, which includes consumables, equipment and services for wafer polishing, dicing and cleaning. The majority of revenue is derived from the United States.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.